featured program
Single Tablet per Day: Atripla® Fixed Dose Combination
Bristol-Myers Squibb, Gilead and Merck worked together to develop and market Atripla®, a fixed dose combination drug that makes life easier for people living with HIV/AIDS by reducing the number of pills to be taken each day.